-
公开(公告)号：US20230089969A1
公开(公告)日：2023-03-23
申请号：US17817033
申请日：2022-08-03
Applicant: GENMAB A/S , BioNTech SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Friederike GIESEKE , Ugur SAHIN
IPC: C07K16/28 , A61K39/395 , G01N33/569
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
公开(公告)号：US20230087745A1
公开(公告)日：2023-03-23
申请号：US17821837
申请日：2022-08-24
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ , Edward VAN DEN BRINK , Dennis VERZIJL
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20230087164A1
公开(公告)日：2023-03-23
申请号：US17795318
申请日：2021-02-04
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Ugur SAHIN , Alexander MUIK , Isil ALTINTAS , Ulf FORSSMANN , Kate SASSER , Maria JURE-KUNKEL , Manish GUPTA
Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer. The method comprises administering to a subject, a binding agent comprising a first binding region binding to human CD137 and a second binding region binding to human PD-L1. The amount of binding agent administered in each treatment cycle is preferably about 0.3-5 mg/kg body weight or about 25-400 mg in total.
-
公开(公告)号：US20220033510A1
公开(公告)日：2022-02-03
申请号：US17360438
申请日：2021-06-28
Applicant: GENMAB A/S , BioNTech SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Friederike GIESEKE , Ugur SAHIN
IPC: C07K16/28 , A61K39/395 , G01N33/569
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
公开(公告)号：US20210369842A1
公开(公告)日：2021-12-02
申请号：US17289602
申请日：2019-11-06
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK
Abstract: The present invention relates to pharmaceutical formulations of binding agents and their use in medicine. In particular, the invention relates to pharmaceutical formulations of binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the pharmaceutical formulations of the invention and to methods for producing pharmaceutical formulations.
-
Patent Agency Ranking
公开(公告)号：US20230310599A1
公开(公告)日：2023-10-05
申请号：US18023808
申请日：2021-09-02
Applicant: GENMAB A/S
Inventor： Hreinn BENONISSON , Jim MIDDELBURG , Thorbald VAN HALL , Isil ALTINTAS , Kristel KEMPER , Janine SCHUURMAN , Katy Ann LLOYD , Vitalijs OVCINNIKOVS , Gijsbertus ZOM
CPC classification number: A61K39/42 , A61P35/00 , A61P37/04 , A61K2039/545
Abstract: The present invention relates to combination therapy within the field of oncology; in particular to combination therapy with vaccines and binding agents binding to CD3 and to a target antigen on tumor cells.
-
公开(公告)号：US20220389101A1
公开(公告)日：2022-12-08
申请号：US17739940
申请日：2022-05-09
Applicant: GENMAB A/S
Inventor： Rik RADEMAKER , Isil ALTINTAS , Patrick ENGELBERTS , Janine SCHUURMAN , Paul PARREN
Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
-
公开(公告)号：US20210317225A1
公开(公告)日：2021-10-14
申请号：US17345628
申请日：2021-06-11
Applicant: GENMAB A/S , BioNTech SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Friederike GIESEKE , Ugur SAHIN
IPC: C07K16/28 , A61K39/395 , G01N33/569
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
公开(公告)号：US20210163616A1
公开(公告)日：2021-06-03
申请号：US17172694
申请日：2021-02-10
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20200247899A1
公开(公告)日：2020-08-06
申请号：US16855703
申请日：2020-04-22
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Friederike GIESEKE , Ugur SAHIN
IPC: C07K16/28 , A61K39/395 , G01N33/569
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.014 seconds)
